洛陽鉬業(03993.HK)引入寧德時代(300750.SZ)子企成第二大股東
洛陽鉬業(03993.HK)公布,洛陽國宏、四川時代及寧德時代(300750.SZ)已於昨日(10月31日)簽訂投資協議,據此,洛陽國宏同意以其持有的洛礦集團100%股權出資給四川時代,以對四川時代進行增資,作價約267.49億元人民幣。
完成後,洛礦集團將成為四川時代的全資附屬,四川時代將通過洛礦集團持有公司24.68%的股權,成為公司第二大股東。而四川時代從寧德時代全資子公司變更為控股子公司。
四川時代及寧德時代無意謀求公司的控制權;除擬議交易外,四川時代及寧德時代未來36個月內無進一步增持公司股份的計劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.